The newest weight-loss drug may change not only appetites, but also knees. That’s the intriguing implication of the pooled results of two large-scale trials of retatrutide, the most potent GLP-1-agonist drug yet developed.
In the studies, which were presented on Sunday at the annual meeting of the American College of Rheumatology in Orlando and simultaneously published in the New England Journal of Medicine , more than 1000 men and women with obesity and painful knee osteoarthritis began taking retatrutide injections, or a placebo, once a week at varying doses. (The research was funded by Eli Lilly and Company, the maker of the drug.)
Gift articles to anyone you choose each month when you subscribe.
